Gevo stock price target maintained at $14 by H.C. Wainwright

H.C. Wainwright has reaffirmed its Buy rating and $80 price target for CRISPR Therapeutics (NASDAQ:CRSP) stock. The target represents substantial upside from the current price of $50.44, even though the stock has slipped 9% over the last week. Analysts collectively anticipate a 70% upside potential to their average target price.

CRISPR recently unveiled Phase 1b severe hypertriglyceridemia data for CTX310, which will be showcased as a late-breaking oral presentation at the American Heart Association conference on November 9 at 8:00 a.m. CT. The company highlighted steady dose response, persistent ANGPTL3 suppression, and individual triglyceride reductions reaching 78% at one year. The benchmark for commercial success is a 70% decrease in triglycerides from baseline, or a smaller reduction that brings hypertriglyceridemia patients below 500 mg/dL.

The company maintains no changes to its estimates, valuation, or a 25% probability of approval for CTX310. Presently, CRSP trades above its Fair Value, according to InvestingPro analysis. Interested investors can explore the comprehensive Pro Research Report covering CRSP and over 1,400 US equities.

CRISPR Therapeutics has caught the attention of various analyst firms, showcasing its advancements in gene-editing therapies. Moreover, Citizens has reiterated a Market Outperform rating with a price target of $80, commending the company's successful commercialization of a gene-editing-based cell therapy.